Payment overview · 2025
General Payments
$590.01
33 reported records · 15 companies
Healthcare provider profile · identity verified
Genna Siemons, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1902210388
Verified facts
What the public records show
CMS Open Payments records show Genna Siemons, M.D. received $590.01 in general payments during 2025 across 33 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 13.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.25 | 13.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.99 | 11.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.87 | 11.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.97 | 9.7% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $48.32 | 8.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.02 | 8.0% | 3 | 2025 |
| MML US, Inc. | Unresolved — no canonical attribution shown | $43.12 | 7.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.88 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.01 | 4.9% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $27.52 | 4.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.13 | 3.8% | 1 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $18.86 | 3.2% | 1 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $18.81 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.93 | 2.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.33 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $590.01 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.25 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.97 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.97 | 4 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $48.32 | 2 | 2025 |
Source payment records
|
|||||
| ReActiv8 Normalized: reactiv8 |
Device | MML US, Inc. | $43.12 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.70 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.30 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.01 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $27.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 79 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 278 | 70 |
| Losartan Potassium | Losartan Potassium | 264 | 59 |
| Lisinopril | Lisinopril | 176 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 48 |
| Omeprazole | Omeprazole | 137 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 29 |
| Gabapentin | Gabapentin | 116 | 20 |
| Trazodone Hcl | Trazodone Hcl | 109 | 20 |
| Furosemide | Furosemide | 108 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 26 |
| Sertraline Hcl | Sertraline Hcl | 106 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 19 |
| Eliquis | Apixaban | 79 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 23 |
| Potassium Chloride | Potassium Chloride | 78 | 18 |
| Montelukast Sodium | Montelukast Sodium | 77 | 19 |
| Pregabalin | Pregabalin | 74 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 20 |
| Metformin Hcl Er | Metformin Hcl | 65 | 15 |
| Jardiance | Empagliflozin | 60 | 13 |
| Tramadol Hcl | Tramadol Hcl | 60 | suppressed |
| Alprazolam | Alprazolam | 59 | 13 |
| Famotidine | Famotidine | 53 | suppressed |
| Metformin Hcl | Metformin Hcl | 53 | 17 |
| Alendronate Sodium | Alendronate Sodium | 50 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 18 |
| Prednisone | Prednisone | 47 | 26 |
| Celecoxib | Celecoxib | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Simvastatin | Simvastatin | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Cefdinir | Cefdinir | 40 | 33 |
| Cephalexin | Cephalexin | 37 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Meloxicam | Meloxicam | 35 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 16 |
| Azithromycin | Azithromycin | 34 | 28 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Ozempic | Semaglutide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Auryxia | Ferric Citrate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $590.01 · 33 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, ELIQUIS, Evoke, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, ReActiv8, Rybelsus, UBRELVY, VRAYLAR, VYJUVEK, VYNDAQEL, Wegovy, ZORYVE, ZURZUVAE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error